ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
Condition(s) studied
Investigational drug(s) / intervention(s)
ECMO support: ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
PROSpect protocolized therapies: PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure. The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine.
Study summary
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives.
The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.
Eligibility
Primary outcome measure(s)
- Change in functional status — baseline and 1 year after pediatric intensive care unit discharge
This primary natural history outcome is measured among usual care extracorporeal membrane oxygenation (ECMO) patients. This outcome is the change in functional status as measured at baseline and 12 months after pediatric intensive care unit (PICU) discharge. The instrument is the functional status scale score. The baseline measure will be made within 96 hours of ECMO initiation and reflect patient's status in the week prior to ECMO. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning. - Change in health-related quality of life — baseline and 1 year after pediatric intensive care unit discharge
This primary natural history outcome is measured among usual care ECMO patients. This outcome is the change in the health-related quality of life as measured at baseline and 12 months after PICU discharge. The instrument is the age-appropriate Version 4.0 Pediatric Quality of Life Inventory (PedsQL 4.0) generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales ranges from 0 to 100, with higher scores indicating fewer problems. PedsQL 4.0 Generic Core Scales is a 23-item scale with 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales consist of 36-45 questions, depending on age, with 5 domains: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning. - The proportion of children with a new morbidity — baseline and 1 year after pediatric intensive care unit discharge
This primary natural history outcome is measured among usual care ECMO patients. A new morbidity is defined as a change in the functional status scale score instrument by 3 or more, as previously described. This outcome will report the proportion of children who acquire a new morbidity as measured at baseline and 12 months after PICU discharge. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning. - All-cause mortality at hospital discharge or 90-days — 90 days after the day of illness on which patients from the two cohorts are matched
This primary comparative short-term outcome is measured among both usual care ECMO and Prone and Oscillation Pediatric Clinical Trial (PROSpect) protocolized therapy groups. The outcome compares the 90-day mortality for matched children in the two groups. The endpoint is 90 days after the day of illness on which patients from the two cohorts are matched or hospital discharge. - Comparative change in one-year functional status — baseline and 1 year after pediatric intensive care unit discharge
This primary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. The outcome compares the change in the functional status as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the functional status scale score. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning. - Comparative change in one-year health-related quality of life — baseline and 1 year after pediatric intensive care unit discharge
This primary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. The outcome compares the change in the health-related quality of life as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the change in the age-appropriate PedsQL 4.0 generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales ranges from 0 to 100, with higher scores indicating fewer problems. PedsQL 4.0 Generic Core Scales is a 23-item scale with 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales consist of 36-45 questions, depending on age, with 5 domains: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.
Trial sites (95)
| Facility | City | Region | Status |
|---|---|---|---|
| Children's of Alabama | Birmingham | Alabama | |
| Phoenix Children's Hospital | Phoenix | Arizona | |
| Arkansas Children's Hospital | Little Rock | Arkansas | |
| Loma Linda University Children's Hospital | Loma Linda | California | |
| UCLA Mattel Children's Hospital | Los Angeles | California | |
| Valley Children's Hospital | Madera | California | |
| UCSF Benioff Children's Hospital Oakland | Oakland | California | |
| Children's Hospital of Orange County | Orange | California | |
| Lucile Packard Children's Hospital Stanford | Palo Alto | California | |
| UCSF Benioff Children's Hospital - San Francisco | San Francisco | California | |
| Children's Hospital Colorado | Aurora | Colorado | |
| Connecticut Children's Medical Center | Hartford | Connecticut | |
| Yale New Haven Children's Hospital | New Haven | Connecticut | |
| Nemours Children's Hospital, Delaware | Wilmington | Delaware | |
| UF Health Shands Children's Hospital | Gainesville | Florida | |
| Orlando Health Arnold Palmer Hospital for Children | Orlando | Florida | |
| Nemours Children's Hospital, Florida | Orlando | Florida | |
| Children's Healthcare of Atlanta | Atlanta | Georgia | |
| Kapi'olani Medical Center for Women & Children | Honolulu | Hawaii | |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | |
| Comer Children's Hospital | Chicago | Illinois | |
| OSF Healthcare Children's Hospital of Illinois | Peoria | Illinois | |
| Riley Hospital for Children | Indianapolis | Indiana | |
| University of Iowa Health Care Stead Family Children's Hospital | Iowa City | Iowa | |
| Norton Children's Hospital | Louisville | Kentucky | |
| Ochsner LSU Health Shreveport | Shreveport | Louisiana | |
| Johns Hopkins Children's Center | Baltimore | Maryland | |
| Boston Children's Hospital | Boston | Massachusetts | |
| University of Michigan - Mott Children's Hospital | Ann Arbor | Michigan | |
| Children's Hospital of Michigan | Detroit | Michigan | |
| Helen DeVos Children's Hospital | Grand Rapids | Michigan | |
| Children's Minnesota Hospital | Minneapolis | Minnesota | |
| Mayo Eugenio Litta Children's Hospital | Rochester | Minnesota | |
| Children's Mercy | Kansas City | Missouri | |
| Cardinal Glennon Children's Hospital | St Louis | Missouri | |
| St. Louis Children's Hospital | St Louis | Missouri | |
| Children's Nebraska | Omaha | Nebraska | |
| UNM Children's Hospital | Albuquerque | New Mexico | |
| John R. Oishei Children's Hospital | Buffalo | New York | |
| Hassenfeld Children's Hospital at NYU Langone | New York | New York |
+ 55 more sites — see the full list on the official registry below.
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05388708 on ClinicalTrials.gov ↗ ← All trials in Sweden